Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.72
OTCPK:AMAR's Cash-to-Debt is ranked lower than
69% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. OTCPK:AMAR: 2.72 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:AMAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: No Debt
Current: 2.72
0
No Debt
Equity-to-Asset 0.36
OTCPK:AMAR's Equity-to-Asset is ranked lower than
81% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OTCPK:AMAR: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:AMAR' s Equity-to-Asset Range Over the Past 10 Years
Min: -34.67  Med: -7.49 Max: 0.95
Current: 0.36
-34.67
0.95
Debt-to-Equity 0.87
OTCPK:AMAR's Debt-to-Equity is ranked lower than
83% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. OTCPK:AMAR: 0.87 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:AMAR' s Debt-to-Equity Range Over the Past 10 Years
Min: -12.42  Med: -0.77 Max: 26
Current: 0.87
-12.42
26
Debt-to-EBITDA -0.54
OTCPK:AMAR's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. OTCPK:AMAR: -0.54 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:AMAR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.01  Med: -1.23 Max: -0.08
Current: -0.54
-7.01
-0.08
Piotroski F-Score: 3
Altman Z-Score: 2.66
WACC vs ROIC
14.98%
336.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -308.44
OTCPK:AMAR's Operating Margin % is ranked lower than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. OTCPK:AMAR: -308.44 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:AMAR' s Operating Margin % Range Over the Past 10 Years
Min: -55500  Med: -2565.82 Max: -231.08
Current: -308.44
-55500
-231.08
Net Margin % -313.64
OTCPK:AMAR's Net Margin % is ranked lower than
56% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. OTCPK:AMAR: -313.64 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:AMAR' s Net Margin % Range Over the Past 10 Years
Min: -65100  Med: -2006.85 Max: 10120
Current: -313.64
-65100
10120
ROA % -72.63
OTCPK:AMAR's ROA % is ranked lower than
69% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. OTCPK:AMAR: -72.63 )
Ranked among companies with meaningful ROA % only.
OTCPK:AMAR' s ROA % Range Over the Past 10 Years
Min: -1489.22  Med: -449.82 Max: 203.21
Current: -72.63
-1489.22
203.21
ROC (Joel Greenblatt) % -3518.52
OTCPK:AMAR's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. OTCPK:AMAR: -3518.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:AMAR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -220400  Med: -15308.33 Max: 24000
Current: -3518.52
-220400
24000
GuruFocus has detected 2 Warning Signs with Amarillo Biosciences Inc OTCPK:AMAR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:AMAR's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AMAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:STU:BMP, OTCPK:CELZ, TSXV:RP, OTCPK:GOVX, OTCPK:BTHE, OTCPK:GLPH, BOM:531726, TSXV:COT, NAS:HTBX, TSXV:KNE, XCNQ:LILY, TSXV:APC, OSL:ABT, OTCPK:PKPH, OTCPK:CGYG, XSAT:APTA, WAR:RDG, TSX:CTX, OTCPK:AURX, XSAT:CLINE B » details
Traded in other countries:FZX.Germany,
Headquarter Location:USA
Amarillo Biosciences Inc is a specialty biopharmaceutical company. The Company is engaged in developing biologics for the treatment of human and animal diseases including influenza, hepatitis C, thrombocytopenia, and other indications.

Amarillo Biosciences Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form.

Top Ranked Articles about Amarillo Biosciences Inc

Amarillo Biosciences First-Half 2018 Business Update

Ratios

vs
industry
vs
history
PB Ratio 19.42
AMAR's PB Ratio is ranked lower than
87% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMAR: 19.42 )
Ranked among companies with meaningful PB Ratio only.
AMAR' s PB Ratio Range Over the Past 10 Years
Min: 8.1  Med: 13.42 Max: 20.59
Current: 19.42
8.1
20.59
PS Ratio 165.00
AMAR's PS Ratio is ranked lower than
63% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMAR: 165.00 )
Ranked among companies with meaningful PS Ratio only.
AMAR' s PS Ratio Range Over the Past 10 Years
Min: 1.43  Med: 25.71 Max: 2090
Current: 165
1.43
2090
EV-to-EBIT -11.29
AMAR's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AMAR: -11.29 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAR' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.4  Med: -1.3 Max: 12
Current: -11.29
-14.4
12
EV-to-EBITDA -11.29
AMAR's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AMAR: -11.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.4  Med: -1.3 Max: 12
Current: -11.29
-14.4
12
EV-to-Revenue 34.80
AMAR's EV-to-Revenue is ranked lower than
63% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AMAR: 34.80 )
Ranked among companies with meaningful EV-to-Revenue only.
AMAR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 29.4 Max: 1369.8
Current: 34.8
1.5
1369.8
Current Ratio 1.45
AMAR's Current Ratio is ranked lower than
83% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AMAR: 1.45 )
Ranked among companies with meaningful Current Ratio only.
AMAR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 32.51
Current: 1.45
0.01
32.51
Quick Ratio 1.45
AMAR's Quick Ratio is ranked lower than
78% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AMAR: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
AMAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.09 Max: 32.51
Current: 1.45
0.01
32.51
Days Inventory 36.50
AMAR's Days Inventory is ranked higher than
83% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. AMAR: 36.50 )
Ranked among companies with meaningful Days Inventory only.
AMAR' s Days Inventory Range Over the Past 10 Years
Min: 36.5  Med: 115.58 Max: 115.58
Current: 36.5
36.5
115.58
Days Sales Outstanding 2.37
AMAR's Days Sales Outstanding is ranked higher than
96% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AMAR: 2.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.37
Current: 2.37
0
2.37
Days Payable 1.00
AMAR's Days Payable is ranked higher than
93% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. AMAR: 1.00 )
Ranked among companies with meaningful Days Payable only.
AMAR' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 4478.27 Max: 74003.75
Current: 1
1
74003.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.80
AMAR's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AMAR: -4.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -78.4  Med: -21.8 Max: -4.8
Current: -4.8
-78.4
-4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 33.00
AMAR's Price-to-Net-Cash is ranked lower than
73% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. AMAR: 33.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AMAR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.85  Med: 7.72 Max: 33
Current: 33
3.85
33
Price-to-Net-Current-Asset-Value 33.00
AMAR's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. AMAR: 33.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AMAR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.19  Med: 4.44 Max: 33
Current: 33
2.19
33
Price-to-Tangible-Book 33.00
AMAR's Price-to-Tangible-Book is ranked lower than
88% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. AMAR: 33.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AMAR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.01  Med: 4.16 Max: 166.3
Current: 33
2.01
166.3
Price-to-Median-PS-Value 6.60
AMAR's Price-to-Median-PS-Value is ranked higher than
50% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AMAR: 6.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.92 Max: 112.11
Current: 6.6
0.14
112.11
Earnings Yield (Greenblatt) % -8.86
AMAR's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AMAR: -8.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1198.6  Med: -60 Max: 37
Current: -8.86
-1198.6
37

More Statistics

Revenue (TTM) (Mil) $0.31
EPS (TTM) $ -0.04
Beta2.14
Volatility56.96%
52-Week Range $0.15 - 0.35
Shares Outstanding (Mil)34.67

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for AMAR

Headlines

Articles On GuruFocus.com
Amarillo Biosciences First-Half 2018 Business Update Aug 23 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}